Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1


Disclosures: ET and SS report research support from Novartis; AS and CP are employees of Novartis; IG is an employee of GSK; AM is an employee of AstraZeneca and has stock ownership of GSK, Novartis and AstraZeneca; AS has stock ownership of Novartis; AJ reports consultancy, speakers bureau, board membership and travel support of Janssen, Roche, Abbvie, Sanofi, Amgen, Novartis and Mundipharma; PP reports consultancy, research funding, honoraria and board membership of Genesis, Roche, Abbvie, Novartis, Takeda, Janssen and Sandoz; PH reports honoraria, speakers bureau, research funding and travel support from Janssen, Abbvie, Gilead, Pharmacyclics and Roche; JM reports research support from GSK; PB, RS, BJ, AD, DY, FO, LB, DM and HD have no conflicts of interest.

Contributions: ET and SS designed the research; ET, PB, BJ, AD and DY performed laboratory analyses; ET, RS and AM performed statistical analyses, all authors interpreted the data; ET and SS wrote the first draft of the manuscript and all authors contributed to and approved the manuscript.